15.80
-0.55(-3.36%)
Currency In USD
| Previous Close | 16.35 |
| Open | 16.45 |
| Day High | 16.47 |
| Day Low | 15.41 |
| 52-Week High | 31.13 |
| 52-Week Low | 5.49 |
| Volume | 109,112 |
| Average Volume | 219,154 |
| Market Cap | 591.72M |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 14.25 |
| Moving Average 200 Days | 13.58 |
| Change | -0.55 |
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV in Septembe
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
GlobeNewswire Inc.
Jul 01, 2025 8:01 PM GMT
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases inc
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 21, 2025 11:00 AM GMT
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases incl